Search results
Results from the WOW.Com Content Network
Rifaximin, sold under the brand name Xifaxan among others, is a non-absorbable, broad-spectrum antibiotic mainly used to treat travelers' diarrhea. It is based on the rifamycin antibiotics family. Since its approval in Italy in 1987, it has been licensed in more than 30 countries for the treatment of a variety of non-infectius gastrointestinal ...
Fab: fragment, antigen-binding (one arm) F(ab') 2: fragment, antigen-binding, including hinge region (both arms) Fab': fragment, antigen-binding, including hinge region (one arm) Variable fragments: scFv: single-chain variable fragment; di-scFv: dimeric single-chain variable fragment; sdAb: single-domain antibody; BsAb: bispecific monoclonal ...
Site members may follow a research interest, in addition to following other individual members. [10] It has a blogging feature for users to write short reviews on peer-reviewed articles. [ 10 ] ResearchGate indexes self-published information on user profiles to suggest members to connect with others who have similar interests. [ 3 ]
Databases for oncogenomic research are biological databases dedicated to cancer data and oncogenomic research. They can be a primary source of cancer data, offer a certain level of analysis (processed data) or even offer online data mining .
Antagonists will block the binding of an agonist at a receptor molecule, inhibiting the signal produced by a receptor–agonist coupling.. A receptor antagonist is a type of receptor ligand or drug that blocks or dampens a biological response by binding to and blocking a receptor rather than activating it like an agonist.
While odronextamab was on track to potentially become Regeneron's first blood cancer drug, it has a much smaller market opportunity of $200 million compared to other potential launches of the ...
The rifamycin group includes the classic rifamycin drugs as well as the rifamycin derivatives rifampicin (or rifampin), rifabutin, rifapentine, rifalazil and rifaximin. Rifamycin, sold under the trade name Aemcolo, is approved in the United States for treatment of travelers' diarrhea in some circumstances. [1] [2] [3]
In the first NRTI mutations disrupt specific contacts between the inhibitor and the NNRTI binding pocket. An example of this is K103N and K101E which sit at the entrance of the pocket, [18] [19] blocking the entrance/binding of the drug. A second mechanism is the disruption of important interactions on the inside of the pocket.